Equidyne Corporation Announces Contract for Use of INJEX in Outpatient Cancer Therapy.Business/Technology Editors and Health/Medical Writers AMHERST, N.H.--(BW HealthWire)--Jan. 7, 2000 EQUIDYNE CORPORATION (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :INJX) announced today that its partially-owned Germany-based subsidiary, Rosch AG Medizintechnik, i.G. ("Rosch AG"), has signed a contract with Acanthos GmbH for outpatient cancer therapy using the INJEX(TM) needle-free injection system. This agreement, for distribution rights in Germany, is expected to generate revenues to Rosch AG of approximately $950,000 (1.8 million Deutsche Marks) over a 24-month period. Shipments are expected to begin in March 2000, after completion of ongoing clinical studies. Acanthos GmbH, based in Hanover, Germany, specializes in providing outpatient cancer therapy services utilizing a network of over 50 nursing home-healthcare providers throughout Germany. Acanthos GmbH works closely with, and is currently conducting the clinical study at the Fraunhofer Institute, a leading independent academic and clinical research institution also based in Hanover, Germany. Patient compliance with prescribed drug regimens is a problem since most patients are afraid of conventional needle syringes. The virtually pain-free INJEX(TM) System provides a real solution to this problem and should result in significantly improved acceptance of the cancer therapy, thereby helping to reduce overall healthcare costs by allowing treatment to be administered on an out-patient basis. Andy Rosch, Chief Executive Officer of Rosch AG, stated, "We are pleased to have Acanthos GmbH as our partner for the cancer therapy market. This is just the first of many new indications that are expected to use the INJEX(TM) System for the delivery of pharmaceuticals." Equidyne Corporation, through Equidyne Systems, Inc., a wholly-owned subsidiary based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , and Rosch AG Medizintechnik, i.G. ("Rosch AG"), a partially-owned subsidiary based in Berlin, Germany (Additional information at: www.roeschnet.com), is focused on becoming the worldwide leader in needle-free drug delivery systems for subcutaneous subcutaneous /sub·cu·ta·ne·ous/ (sub?ku-ta´ne-us) beneath the skin. sub·cu·ta·ne·ous adj. Abbr. s.c., SQ Located, found, or placed just beneath the skin; hypodermic. and intramuscular injections Noun 1. intramuscular injection - an injection into a muscle injection, shot - the act of putting a liquid into the body by means of a syringe; "the nurse gave him a flu shot" . Rosch AG is responsible for the European market, while Equidyne is responsible for the U.S., Canada, South America South America, fourth largest continent (1991 est. pop. 299,150,000), c.6,880,000 sq mi (17,819,000 sq km), the southern of the two continents of the Western Hemisphere. and the Asian markets. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless pain·less adj. Free from complication or pain: a painless operation. pain  less·ly adv. injection
through the skin in a fraction of a second, and eliminates needle stick
and disposal problems. For medications requiring injection, we believe
the INJEX(TM) System is by far the most comfortable and economical
product on the market.
The statements contained in this news release that are not purely historical are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that may involve risks and uncertainties. The Company's actual results may differ significantly from the results contained in the forward-looking statements. Factors that might cause such differences include, but are not limited to, the effect of losses and other factors on the Company's credit facilities credit facilities npl → facilidades fpl de crédito credit facilities npl → facilités fpl de paiement credit facilities , business and results of operations; the Company's limited capital resources and its ability to fulfill its existing obligations and ongoing capital needs; risks associated with excess or obsolete inventory Obsolete Inventory Term that refers to inventory that is at the end of its product life cycle and has not seen any sales or usage for a set period of time usually determined by the industry. This type of inventory has to be written down and can cause large losses for a company. ; the potential impairment Impairment 1. A reduction in a company's stated capital. 2. The total capital that is less than the par value of the company's capital stock. Notes: 1. This is usually reduced because of poorly estimated losses or gains. 2. of assets; the Company's dependence on key customers and their financial viability; the impact of competition; and the Company's abilities to effectively manage growth. These and other risk factors are discussed in the Company's filings on Forms 8-K, 10-QSB and 10-KSB. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion